{"entity":{"id":"nct05720130","kind":"trial","name":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","aka":[],"tldr":"A phase 1/2 trial of [²¹²Pb]Pb-ADVC001 (Phase 1b) in prostate cancer, run by AdvanCell Pty Limited, now recruiting.","summary":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). is a phase 1/2 interventional study registered as NCT05720130 by AdvanCell Pty Limited, with 100 participants planned, started 2023-03-15 and due to reach its primary completion in 2029-01-31. Interventions recorded: [²¹²Pb]Pb-ADVC001 (Phase 1b) and [²¹²Pb]Pb-ADVC001 (Phase 2a).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05720130","url":"https://clinicaltrials.gov/study/NCT05720130"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05720130","phase":"1/2","setting":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","sponsor":"AdvanCell Pty Limited","enrolled":100,"outcomes":[]},"route":"/trials/nct05720130/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}